“Researchers in Israel studied 6,000 adults with no prior history of cancer, who either underwent bariatric surgery or took glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide (Saxenda), exenatide (Byetta) or dulaglutide (Trulicity). The drugs work by mimicking the GLP-1 hormone in the body, which lowers blood sugar levels and makes people feel fuller for longer.

Although those who had bariatric surgery lost around double the weight of those on weight-loss medication, the study, presented at the European Congress on Obesity in Malaga, Spain, and published in The Lancet’s eClinicalMedicine, found the reduction in cancer risk was broadly the same.

Bariatric surgery reduces the risk of cancer by 30-42%, the researchers said. Therefore, accounting for the relative advantage of surgery in reducing patients’ weight, the authors found weight-loss drugs were more effective at preventing obesity-related cancer.”

From The Guardian.